Safety and Efficacy of Bevacizumab (Avastin) in High-Risk Corneal Transplant Survival

Safety and Efficacy of Bevacizumab (Avastin) in High-Risk Corneal Transplant Survival
MEEI Protocol ID
National Clinical Trial (NCT) Number
Corneal Transplant
National Institute of Health
Principal Investigator
Reza Dana, M.D., MPH, M.Sc.
Study Design
Treatment, parallel assignment, Double blind (Subject, Care giver, Investigator), Randomized, Placebo Control, Safety/Efficacy Study
Study Objective
To test the effectiveness of a drug, bevacizumab (Avastin), in preventing blood vessels that often occur after a corneal transplantation which are considered at “high-risk” for rejection. In many cases these blood vessels lead to the graft rejection and eventual failure of the corneal transplant. It is hoped that this treatment will increase the chances of corneal graft survival.
Who is Eligible
Patients enrolled in this trial are planning on having a corneal transplant and are considered to be at “high-risk” for rejection. Corneal neovascularization is a complication which can worsen the prognosis of the corneal transplant and put the transplant at higher risk of rejection.
Subject Enrollment
We are currently enrolling individuals who will be having corneal transplant who meet the study eligibility criteria.
Study Procedures
Participants in this trial will be randomized to receive either an Avastin treatment or a placebo treatment, which will be injected beneath the conjunctiva at the conclusion of the surgery and then applied as an eye drop for 4 weeks following the surgery.
Including the procedural visit, this study involves up to 10 visits to our cornea clinic at the Massachusetts Eye and Ear Infirmary
For More Information Ophthalmology Clinical Research Office

Click here to return to the Ophthalmology Clinical Research page.